# Ardelyx Inc. (ARDX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.40B  
**Price:** $5.83 (+3.83%)

> Ardelyx Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class medicines to address unmet medical needs in gastrointestinal and cardio-renal diseases. The company employs an innovative platform that identifies new biological mechanisms and pathways, enabling the creation of potent therapies designed to act locally in the gastrointestinal tract, thereby minimizing systemic side effects and drug-drug interactions common with traditional treatments. Its key products include IBSRELA (tenapanor), indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH (tenapanor), used to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to or intolerance of phosphate binders. Ardelyx Inc. targets patients with significant unmet needs in these therapeutic areas, advancing patient care through targeted, efficacious treatments. Founded in 2007 and headquartered in Waltham, Massachusetts, Ardelyx Inc. plays a vital role in the biopharmaceutical sector by delivering novel solutions for challenging medical conditions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $407M | $368M | -$41M | -$62M | — |
| 2024 | $334M | $283M | -$28M | -$39M | — |
| 2023 | $124M | $107M | -$63M | -$66M | — |
| 2022 | $52M | $48M | -$64M | -$67M | — |
| 2021 | $10M | $9M | -$154M | -$158M | — |
| 2020 | $8M | $7M | -$91M | -$94M | — |
| 2019 | $5M | $5M | -$91M | -$95M | — |
| 2018 | $3M | $2M | -$91M | -$91M | — |
| 2017 | $42M | $34M | -$65M | -$64M | — |
| 2015 | $24M | $24M | -$29M | -$30M | — |
| 2014 | $32M | — | -$2M | -$3M | — |
| 2013 | $29M | — | -$3M | -$7M | — |
| 2012 | $5M | — | -$9M | -$10M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $502M | $335M | $167M | $68M | $203M |
| 2024 | $436M | $262M | $173M | $65M | $151M |
| 2023 | $298M | $131M | $167M | $21M | $50M |
| 2022 | $190M | $92M | $98M | $96M | $27M |
| 2021 | $150M | $67M | $83M | $72M | $32M |
| 2020 | $202M | $75M | $126M | $91M | $51M |
| 2019 | $260M | $73M | $187M | $181M | $50M |
| 2018 | $183M | $68M | $116M | $79M | $52M |
| 2017 | $158M | $19M | $139M | $75M | — |
| 2015 | $117M | $8M | $109M | $107M | — |
| 2014 | $113M | $53M | $61M | $107M | — |
| 2013 | $43M | $50M | -$63M | $34M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$42M | $1M | -$44M |
| 2024 | -$45M | $1M | -$46M |
| 2023 | -$90M | $344,000 | -$90M |
| 2022 | -$70M | $55,000 | -$70M |
| 2021 | -$153M | $2M | -$154M |
| 2020 | -$81M | $324,000 | -$82M |
| 2019 | -$76M | $325,000 | -$77M |
| 2018 | -$70M | $311,000 | -$71M |
| 2017 | -$65M | $2M | -$68M |
| 2016 | -$93M | $5M | -$97M |
| 2015 | -$72M | $3M | -$75M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ARDX)